secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2023-10-02T23:59:59+00:00
Accession:  0000950170-23-051127
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 8.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics announces up to $130M private placement led by RA Capital to fund SAB-142 T1D trial
--------------------------------------------------------------------------------

- Initial closing of $7.5M from Series A-1 Preferred; potential total $130M via warrants and further tranches.
- Funds to advance SAB-142 into Phase II for type 1 diabetes; Phase I expected Q4 2023.
- Investors include RA Capital, BVF Partners, Sessa Capital, Commodore Capital, RTW Investments, Marshall Wace, JDRF T1D Fund.
- Andrew Moin (Sessa Capital) appointed to Board of Directors effective upon closing.
- Preferred stock convertible at $0.63/share; requires stockholder approval; warrants exercisable for additional shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017023051127/0000950170-23-051127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017023051127/sabs-20230929.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-051127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer